Literature DB >> 35441664

A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.

Julia Cadrin-Tourigny1,2, Laurens P Bosman3,4, Anna Nozza5, Weijia Wang1, Rafik Tadros2, Aditya Bhonsale1, Mimount Bourfiss4, Annik Fortier5, Øyvind H Lie6,7, Ardan M Saguner8, Anneli Svensson9, Antoine Andorin2, Crystal Tichnell1, Brittney Murray1, Katja Zeppenfeld10, Maarten P van den Berg11, Folkert W Asselbergs3,4,12, Arthur A M Wilde13, Andrew D Krahn14, Mario Talajic2, Lena Rivard2, Stephen Chelko1, Stefan L Zimmerman15, Ihab R Kamel15, Jane E Crosson1, Daniel P Judge1, Sing Chien Yap16, Jeroen F van der Heijden4, Harikrishna Tandri1, Jan D H Jongbloed17, Marie Claude Guertin5, J Peter van Tintelen3,18, Pyotr G Platonov19, Firat Duru8, Kristina H Haugaa6,7, Paul Khairy2, Richard N W Hauer3,4, Hugh Calkins1, Anneline S J M Te Riele3,4, Cynthia A James1.   

Abstract

AIMS: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients. METHODS AND
RESULTS: Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44-9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73-0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92-0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.3% reduction of ICD placements with the same proportion of protected patients (P < 0.001).
CONCLUSION: Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.

Entities:  

Keywords:  Arrhythmogenic right ventricular cardiomyopathy; Implantable cardioverter-defibrillators; Sudden cardiac death; Ventricular arrhythmias

Mesh:

Year:  2022        PMID: 35441664      PMCID: PMC9392651          DOI: 10.1093/eurheartj/ehac180

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   35.855


  18 in total

1.  Multiple imputation of missing blood pressure covariates in survival analysis.

Authors:  S van Buuren; H C Boshuizen; D L Knook
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.

Authors:  Aditya Bhonsale; Cynthia A James; Crystal Tichnell; Brittney Murray; Dmitri Gagarin; Binu Philips; Darshan Dalal; Ryan Tedford; Stuart D Russell; Theodore Abraham; Harikrishna Tandri; Daniel P Judge; Hugh Calkins
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

3.  Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.

Authors:  Laurens P Bosman; Arjan Sammani; Cynthia A James; Julia Cadrin-Tourigny; Hugh Calkins; J Peter van Tintelen; Richard N W Hauer; Folkert W Asselbergs; Anneline S J M Te Riele
Journal:  Heart Rhythm       Date:  2018-02-03       Impact factor: 6.343

4.  Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria.

Authors:  Frank I Marcus; William J McKenna; Duane Sherrill; Cristina Basso; Barbara Bauce; David A Bluemke; Hugh Calkins; Domenico Corrado; Moniek G P J Cox; James P Daubert; Guy Fontaine; Kathleen Gear; Richard Hauer; Andrea Nava; Michael H Picard; Nikos Protonotarios; Jeffrey E Saffitz; Danita M Yoerger Sanborn; Jonathan S Steinberg; Harikrishna Tandri; Gaetano Thiene; Jeffrey A Towbin; Adalena Tsatsopoulou; Thomas Wichter; Wojciech Zareba
Journal:  Eur Heart J       Date:  2010-02-19       Impact factor: 29.983

5.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

6.  Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?

Authors:  Kenneth A Ellenbogen; Joseph H Levine; Ronald D Berger; James P Daubert; Stephen L Winters; Eugene Greenstein; Alaa Shalaby; Andi Schaechter; Haris Subacius; Alan Kadish
Journal:  Circulation       Date:  2006-02-06       Impact factor: 29.690

7.  Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Authors:  Gabriela M Orgeron; Anneline Te Riele; Crystal Tichnell; Weijia Wang; Brittney Murray; Aditya Bhonsale; Daniel P Judge; Ihab R Kamel; Stephan L Zimmerman; Harikrishna Tandri; Hugh Calkins; Cynthia A James
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-02-16

8.  Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.

Authors:  Karel G M Moons; Douglas G Altman; Johannes B Reitsma; John P A Ioannidis; Petra Macaskill; Ewout W Steyerberg; Andrew J Vickers; David F Ransohoff; Gary S Collins
Journal:  Ann Intern Med       Date:  2015-01-06       Impact factor: 25.391

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 10.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard Hauer; Frank Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; N A Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Eur Heart J       Date:  2015-07-27       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.